S1 Guideline onychomycosis.


Journal

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708

Informations de publication

Date de publication:
06 2023
Historique:
received: 15 11 2022
accepted: 04 12 2022
medline: 22 6 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Onychomycosis is a fungal infection of the fingernails and toenails. In Europe, tinea unguium is mainly caused by dermatophytes. The diagnostic workup comprises microscopic examination, culture and/or molecular testing (nail scrapings). Local treatment with antifungal nail polish is recommended for mild or moderate nail infections. In case of moderate to severe onychomycosis, oral treatment is recommended (in the absence of contraindications). Treatment should consist of topical and systemic agents. The aim of this update of the German S1 guideline is to simplify the selection and implementation of appropriate diagnostics and treatment. The guideline was based on current international guidelines and the results of a literature review conducted by the experts of the guideline committee. This multidisciplinary committee consisted of representatives from the German Society of Dermatology (DDG), the German-Speaking Mycological Society (DMykG), the Association of German Dermatologists (BVDD), the German Society for Hygiene and Microbiology (DGHM), the German Society of Pediatric and Adolescent Medicine (DGKJ), the Working Group for Pediatric Dermatology (APD) and the German Society for Pediatric Infectious Diseases (DGPI). The Division of Evidence-based Medicine (dEBM) provided methodological assistance. The guideline was approved by the participating medical societies following a comprehensive internal and external review.

Identifiants

pubmed: 37212291
doi: 10.1111/ddg.14988
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

678-692

Informations de copyright

© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.

Références

Seebacher C, Brasch J, Abeck D, et al. Onychomykose. Leitlinie der Deutschen Dermatologischen Gesellschaft und der Deutschsprachigen Mykologischen Gesellschaft. AWMF-Leitlinien-Register Nr. 013/003. 2006. J Dtsch Dermatol Ges. 2007;5(1):61-66.
Mügge C, Haustein U-F, Nenoff P. Onychomykosen - eine retrospektive Untersuchung zum Erregerspektrum. J Dtsch Dermatol Ges. 2006;4(3):218-228.
Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28(11):1480-1491.
Gnat S, Łagowski D, Nowakiewicz A, et al. Unusual dermatomycoses caused by Nannizzia nana: the geophilic origin of human infections. Infection. 2020;48(3):429-434.
Sacheli R, Cuypers L, Seidel L, et al. Epidemiology of dermatophytes in Belgium: A 5 Years' Survey. Mycopathologia. 2021;186(3):399-409.
Kromer C, Celis D, Hipler U-C, et al. Dermatophyte infections in children compared to adults in Germany: a retrospective multicenter study in Germany. J Dtsch Dermatol Ges. 2021;19(7):993-1001.
Bontems O, Fratti M, Salamin K, et al. Epidemiology of dermatophytoses in Switzerland according to a survey of dermatophytes isolated in Lausanne between 2001 and 2018. J Fungi (Basel). 2020;6(2):95.
Hainsworth S, Hubka V, Lawrie AC, et al. Predominance of Trichophyton interdigitale revealed in podiatric nail dust collections in Eastern Australia. Mycopathologia. 2020;185(1):175-185.
Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol. 2010;28(2):151-159.
Ge G, Yang Z, Li D, et al. Onychomycosis with greenish-black discolorations and recurrent onycholysis caused by Candida parapsilosis. Med Mycol Case Rep. 2019;24:48-50.
Gallo L, Cinelli E, Fabbrocini G, et al. A 15-year retrospective study on the prevalence of onychomycosis in psoriatic vs non-psoriatic patients: A new European shift from dermatophytes towards yeast. Mycoses. 2019;62(8):659-664.
Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66(3):494-502.
Gupta M, Sharma NL, Kanga AK, et al. Onychomycosis: Clinico-mycologic study of 130 patients from Himachal Pradesh, India. Indian J Dermatol Venereol Leprol. 2007;73(6):389-392.
Haghani I, Shams-Ghahfarokhi M, Dalimi Asl A, et al. Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species). Mycoses. 2019;62(2):128-143.
Joyce A, Gupta AK, Koenig L, et al. Fungal diversity and onychomycosis an analysis of 8,816 toenail samples using quantitative PCR and Next-Generation Sequencing. J Am Podiatr Med Assoc. 2019;109(1):57-63.
Kulac M, Acar M, Karaca S, et al. Venous insufficiency in patients with toenail onychomycosis. J Ultrasound Med. 2005;24(8):1085-1089.
Ozkan F, Ozturk P, Ozyurt K, et al. Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis. J Dermatol. 2013;40(2):107-110.
Tchernev G, Penev PK, Nenoff P, et al. Onychomycosis: modern diagnostic and treatment approaches. Wien Med Wochenschr. 2013;163(1-2):1-12.
Sáez de Ocariz MM, Arenas R, Ranero-Juárez GA, et al. Frequency of toenail onychomycosis in patients with cutaneous manifestations of chronic venous insufficiency. Int J Dermatol. 2001;40(1):18-25.
Gupta AK. Types of onychomycosis. Cutis. 2001;68(2 Suppl):4-7.
Andersen PL, Henning MAS, Jemec GBE, et al. Two cases of proximal subungual onychomycosis caused by Trichophyton rubrum in HIV-negative patients during treatment with TNF-α inhibitors combined with methotrexate. Acta Dermatovenerol Croat. 2018;26(4):304-306.
Di Chiacchio N, Noriega LF, Di Gioia Chiacchio N, et al. Superficial black onychomycosis due to Neoscytalidium dimidiatum. J Eur Acad Dermatol Venereol. 2017;31(10):e453-e455.
Tosti A, Baran R, Piraccini BM, et al. “Endonyx” onychomycosis: a new modality of nail invasion by dermatophytes. Acta Derm Venereol. 1999;79(1):52-53.
Mulvaney PM, Telang GH, Jellinek N. Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies. Dermatol Online J. 2015;21(9). 13030/qt3jb3t80q.
Seebacher C, Brasch J, Abeck D, et al. Onychomycosis. Mycoses. 2007;50(4):321-327.
Grimmer H. Histologische Untersuchungen bei Nagelmykosen. In: Die Griseofulvinbehandlung der Dermatomykosen. Berlin, Göttingen, Heidelberg,1962:74-78. Available from: https://link.springer.com/content/pdf/10.1007/978-3-642-86275-5.pdf#page=79 [Last accessed November 15, 2022].
Roberts DT, Evans EG. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol. 1998;138(1):189-190.
Makris N, Megahed M. Zwanzig-Nagel-Dystrophie der Kindheit. Akt Dermatol. 2021;47:279-280.
Bae SH, Jang SH, Won YH. Twenty-nail dystrophy treated with hydroxychloroquine in a patient with alopecia areata. Ann Dermatol. 2019;31(3):359-361.
Uchida T, Uchida Y, Takahashi M, et al. A case of yellow nail syndrome in which intranodal lymphangiography contributed to the diagnosis. Intern Med. 2021;15;60(22):3599-3603
Wollina U. Retronychie - eine seltene Ursache der chronischen proximalen Nagelfalzentzündung. Wien Med Wochenschr. 2021;171(3-4):53-56.
Hengge U R, Bardeli V. Images in clinical medicine. Green nails. N Engl J Med. 2009;360(11):1125.
Ohn J, Yu D-A, Park H, et al. Green nail syndrome: Analysis of the association with onychomycosis. J Am Acad Dermatol. 2020;83(3):940-942.
Abdallah NA, Said M, Mahmoud M T, et al. Onychomycosis: Correlation between the dermoscopic patterns and fungal culture. J Cosmet Dermatol. 2020;19(5):1196-1204.
Kayarkatte M N, Singal A, Pandhi D, et al. Nail dermoscopy (onychoscopy) findings in the diagnosis of primary onychomycosis: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2020;86(4):341-349.
Effendy I, Lecha M, Feuilhade de Chauvin M, et al. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):8-12.
Nenoff P, Mügge C, Herrmann J, et al. Tinea faciei incognito due to Trichophyton rubrum as a result of autoinoculation from onychomycosis. Mycoses. 2007;50(Suppl 2):20-25.
Szepietowski JC, Matusiak L. Trichophyton rubrum autoinoculation from infected nails is not such a rare phenomenon. Mycoses. 2008;51(4):345-346.
Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-1990.
Bosshard PP. Incubation of fungal cultures: how long is long enough? Mycoses. 2011;54(5):e539-e545.
Philpot C. The differentiation of Trichophyton mentagrophytes from T. rubrum by a simple urease test. Sabouraudia. 1967;5(3):189-193.
Su H, Packeu A, Ahmed SA, et al. Species distinction in the Trichophyton rubrum complex. J Clin Microbiol. 2019; 26;57(9):e00352-19.
Nenoff P, Krüger C, Schaller J, et al. Mykologie - ein Update: Teil 2: Dermatomykosen: Klinisches Bild und Diagnostik. J Dtsch Dermatol Ges. 2014;12:749-779.
de Respinis S, Tonolla M, Pranghofer S, et al. Identification of dermatophytes by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Med Mycol. 2013;51(5):514-521.
Nenoff P, Erhard M, Simon JC, et al. MALDI-TOF mass spectrometry - a rapid method for the identification of dermatophyte species. Med Mycol. 2013;51(1):17-24.
Bartosch T, Heydel T, Uhrlaß S, et al. MALDI-TOF MS analysis of bovine and zoonotic Trichophyton verrucosum isolates reveals a distinct peak and cluster formation of a subgroup with Trichophyton benhamiae. Med Mycol. 2018;56(5):602-609.
English MP. Nails and fungi. Br J Dermatol. 1976;94(6):697-701.
Cuchí-Burgos E, Rubio-Casino R, Ballestero-Téllez M, et al. Commercial real time PCR implementation for rapid diagnosis of onychomycosis: A new workflow in a clinical laboratory. Enferm Infecc Microbiol Clin. 2021;39(7):326-329.
Brasch J, Beck-Jendroschek V, Gläser R. Fast and sensitive detection of Trichophyton rubrum in superficial tinea and onychomycosis by use of a direct polymerase chain reaction assay. Mycoses. 2011;54(5):e313-7.
Kupsch C, Ohst T, Pankewitz F, et al. The agony of choice in dermatophyte diagnostics-performance of different molecular tests and culture in the detection of Trichophyton rubrum and Trichophyton interdigitale. Clin Microbiol Infect. 2016;22(8):735.e11-7.
Pankewitz F, Nenoff P, Uhrlaß S, et al. Development of a novel polymerase chain reaction-enzyme-linked immunosorbent assay for the diagnosis of Trichophyton rubrum onychomycosis. Br J Dermatol. 2013;168(6):1236-1242.
Wittig F, Uhrlaß S, Krüger C, et al. Nachweis von pathogenen Dermatophyten mittels Multiplex Real-Time PCR. Derm Prakt Dermatol. 2019;25(2):158-169.
Gupta AK, Nakrieko K-A. Onychomycosis infections. Do polymerase chain reaction and culture reports agree? J Am Podiatr Med Assoc. 2017;107(4):280-286.
Tosti A, Elewski BE. Onychomycosis: Practical approaches to minimize relapse and recurrence. Skin Appendage Disord. 2016;2(1-2):83-87.
Iwanaga T, Ushigami T, Anzawa K, et al. Pathogenic dermatophytes survive in nail lesions during oral Terbinafine treatment for tinea unguium. Mycopathologia. 2017;182(7-8):673-679.
Kupsch C, Czaika V-A, Deutsch C, et al. Trichophyton mentagrophytes - a new genotype of zoophilic dermatophyte causes sexually transmitted infections. J Dtsch Dermatol Ges. 2019;17(5):493-501.
Zaias N, Rebell G, Zaiac MN, et al. Onychomycosis treated until the nail is replaced by normal growth or there is failure. Arch Dermatol. 2000;136(7):940.
Szepietowski JC, Reich A. Stigmatisation in onychomycosis patients: a population-based study. Mycoses. 2009;52(4):343-349.
Pandhi D, Verma P. Nail avulsion: indications and methods (surgical nail avulsion). Indian J Dermatol Venereol Leprol. 2012;78(3):299-308.
Abdo HM. Excellent response of dermatophytoma and nail splitting to nail plate debridement plus topical ciclopirox olamine 1% solution. Skin Appendage Disord. 2021;7(2):127-130.
Potter LP, Mathias SD, Raut M, et al. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18(1):46-52.
Lecha M, Effendy I, Feuilhade de Chauvin M, et al. Treatment options - development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):25-33.
Wollina U, Nenoff P, Haroske G, et al. Diagnostik und Therapie von Nagelerkrankungen. Dtsch Arztebl Int. 2016;113(29-30):509-518.
Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017;7(7):CD010031.
Gupta AK, Foley KA, Mays RR, et al. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis. Br J Dermatol. 2020;182(2):287-299.
Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999;318(7190):1031-1035.
Tietz H-J, Nenoff P. Die Onychomykose - ein Kronjuwel der Dermatologie. Ästhetische Dermatologie & Kosmetologie. 2014;6(2):20-24.
Tietz H-J, Gunkel U. Pilzinfektionen in Zeiten von COVID-19: Schwerpunktthema Mykosen bei Kindern. Derm Prakt Dermatol. 2021;27:236-242.
Appelt L, Nenoff P, Uhrlaß S, et al. Terbinafin-resistente Dermatophytosen und Onychomykose durch Trichophyton rubrum. Hautarzt. 2021;72(10):868-877.
Murad A, Shudell E, Mulligan N. Rowell's syndrome induced by terbinafine. BMJ Case Rep. 2015;2015:bcr2015210360.
Mayser P. Terbinafin: Medikamenteninduzierter Lupus erythematodes und Triggerung psoriatischer Hautveränderungen. Hautarzt. 2016;67(9):724-731.
Dürrbeck A, Nenoff P. Terbinafin: Relevante Arzneimittelinteraktionen und deren Management. Hautarzt. 2016;67(9):718-723.
Tietz H-J. Onychomykose bei Erwachsenen und Kindern. Erfolgreiche Therapie in der täglichen Praxis. Allgemeinarzt. 2017;39:42-47.
Mayser P, Nenoff P, Reinel D, et al. S1-Leitlinie: Tinea capitis. J Dtsch Dermatol Ges. 2020;18(2):161-180.

Auteurs

Pietro Nenoff (P)

Labopart - Medizinische Laboratorien, Labor Leipzig-Mölbis [Labopart - Medical Laboratories, Laboratory Leipzig-Mölbis], Rötha OT Mölbis, Germany.

Dieter Reinel (D)

Praxis für Dermatologie [Dermatology practice], Hamburg, Germany.

Peter Mayser (P)

Biebertal, Germany.

Dietrich Abeck (D)

Hautzentrum Nymphenburg [Nymphenburg Skin Center], München, Munich, Germany.

Guntram Bezold (G)

Hautarztpraxis Neu-Ulm [Neu-Ulm dermatology practice], Neu-Ulm, Germany.

Philipp P Bosshard (PP)

Dermatologische Klinik, Universitätsspital Zürich, Universität Zürich [Department of Dermatology, University Hospital Zurich, University of Zurich], Zürich, Switzerland.

Jochen Brasch (J)

Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein Campus Kiel [Department of dermatology, venereology and allergology, Schleswig-Holstein University hospital, Kiel campus], Kiel, Germany.

Georg Daeschlein (G)

Hautklinik, Städtisches Klinikum Dessau [Skin clinic, Dessau City Hospital], Dessau, Germany.

Isaak Effendy (I)

Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum OWL, Campus Klinikum Bielefeld, Universität Bielefeld [Department of Dermatology, Venereology and Allergology, University Hospital OWL, Campus Bielefeld, University of Bielefeld], Bielefeld, Germany.

Gabriele Ginter-Hanselmayer (G)

Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Graz [University department of dermatology and venereology, Graz Medical University], Graz, Austria.

Yvonne Gräser (Y)

Charité - Universitätsmedizin Berlin, Institut für Mikrobiologie und Infektionsimmunologie, Nationales Konsiliarlabor für Dermatophyten [Charité - University Medicine Berlin, Institute of Microbiology and Infection Immunology, National consultant lab for dermatophytes], Berlin, Germany.

Gudrun Hamm (G)

Hautarztpraxis Dr. med. Gudrun Hamm [Gudrun Hamm MD dermatology practice], Halle (Saale), Germany.

Ulrich Hengge (U)

Hautzentrum [Skin Center] Prof. Hengge, Düsseldorf, Germany.

Uta-Christina Hipler (UC)

Klinik für Hautkrankheiten, Universitätsklinikum Jena [Skin disease clinic, Jena University Hospital], Jena, Germany.

Peter Höger (P)

Abteilung Pädiatrische Dermatologie und Allergologie, Kath. Kinderkrankenhaus Wilhelmstift [Department of Pediatric Dermatology and Allergology, Catholic Children's Hospital Wilhelmstift], Hamburg, Germany.

Alexandra Kargl (A)

Hautärzte am Gasteig, München [Dermatologists am Gasteig, Munich], Germany.

Annette Kolb-Mäurer (A)

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg [Department of dermatology, venereology and allergology, Würzburg University Hospital], Würzburg, Germany.

Constanze Krüger (C)

Labopart - Medizinische Laboratorien, Labor Leipzig-Mölbis [Labopart - Medical Laboratories, Laboratory Leipzig-Mölbis], Rötha OT Mölbis, Germany.

Bartosz Malisiewicz (B)

Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Frankfurt [Department of dermatology, venereology and allergology, Frankfurt University Hospital], Frankfurt am Main, Germany.

Johannes Mayer (J)

Polipraxis AG, Herisau, Switzerland.

Hagen Ott (H)

Abteilung für pädiatrische Dermatologie und Allergologie, Kinder- und Jugendkrankenhaus auf der Bult [Department of dermatology and allergology, Children's and adolescents' hospital auf der Bult], Hannover, Germany.

Uwe Paasch (U)

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Leipzig [Department of dermatology, venereology and allergology, Leipzig University Hospital], Leipzig, Germany.

Martin Schaller (M)

Universitäts-Hautklinik Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Germany.

Silke Uhrlaß (S)

Labopart - Medizinische Laboratorien, Labor Leipzig-Mölbis [Labopart - Medical Laboratories, Laboratory Leipzig-Mölbis], Rötha OT Mölbis, Germany.

Miriam Zidane (M)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Dermatologie, Venerologie und Allergologie [Department of dermatology, venereology and allergology], Division of Evidence-Based Medicine (dEBM), Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH